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Abstract
Background and aims: Preclinical studies have reported 
that activation of peripheral γ-aminobutyric acid A 
(GABAA) receptors may result in analgesia. The current 
study was conducted in young healthy men (n = 30) and 
women (n = 28) to determine whether injections of GABA 
into the masseter muscle reduce pain in a sex-related 
manner.
Methods: The effect of injection of GABA alone, or in com-
bination with the non-inflammatory algogen glutamate, 
was assessed in two separate studies. Lorazepam, a posi-
tive allosteric modulator of the GABAA-receptor, was co-
injected with GABA in both studies to explore the role of 
this receptor in muscle pain responses of healthy human 
volunteers. Masticatory muscle mechanical pain inten-
sity was recorded on an electronic visual analogue scale 
(VAS) while muscle pain sensitivity was assessed by deter-
mining the pressure pain threshold (PPT), tolerance and 
maximal jaw opening (MJO) of the subjects prior to, and 
again after the various intramuscular injections.
Results: Intramuscular injection of GABA alone was 
reported to be significantly more painful, in a concentra-
tion related manner, than saline control injections, and 
this pain was further increased by co-injection of loraze-
pam with GABA. Co-injection of GABA with glutamate was 
found to significantly increase glutamate-evoked mas-
seter muscle pain in men, but not in women. There was 
no effect of injections of either GABA alone, or GABA with 
glutamate, on PPT, tolerance or maximum jaw opening.
Conclusions: Injection of GABA into the human masseter 
muscle appears to excite nociceptors to produce muscle 
pain without a longer term effect on mechanical pain 
sensitivity in the muscle. The findings suggest that GABA-
mediated pain in humans is produced through  peripheral 
GABAA receptor activation. The mechanism underly-
ing the sex-related difference in the effect of GABA on 
 glutamate-evoked muscle pain was speculated to be due 
to a methodological artifact.
Implications: This study was designed to detect analgesic 
rather than algesic effects of peripherally administered 
GABA, and as a result, the concentration of glutamate cho-
sen for injection was close to the maximal pain response 
for healthy women, based on previously determined 
pain-concentration response relationships for glutamate. 
This may explain the finding of greater pain in men than 
women, when GABA and glutamate were co-injected. 
Overall, the findings suggest that activation of peripheral 
GABAA receptors in human masticatory muscle produces 
pain, possibly due to depolarization of the masticatory 
muscle afferent fibers.
Keywords: GABA; glutamate; masseter muscle; muscle 
pain; pressure pain threshold; visual analogue scale.
1   Introduction
In the central nervous system, γ-amino-butyric acid 
(GABA) decreases neuronal excitability by acting on a 
ligand-gated chloride channel, the GABAA receptor and a 
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G-protein coupled receptor, the GABAB receptor [1–4]. Acti-
vation of pre-synaptic GABAA receptors depolarizes the 
central endings of afferent fibers; a process that results 
in decreased release of neurotransmitters from terminal 
endings in the central nervous system [1, 5–10]. Whether 
GABA depolarizes or hyperpolarizes the peripheral 
endings of nerve fibers is not known, however, limited evi-
dence suggests that GABA is much less effective than the 
excitatory amino acid glutamate at exciting rat masseter 
muscle afferent fibers [11].
Activation of peripheral GABAA receptors in the rat 
can attenuate nociceptive input [12–14]. Injections of glu-
tamate made into the rat temporomandibular joint evoke 
reflex jaw muscle activity [15] which can be attenuated 
by co-injection of GABA in a concentration dependent 
manner [12]. The effect of GABA was inhibited by bicucull-
ine, a GABAA receptor antagonist. Subcutaneous adminis-
tration of low concentration muscimol, a selective GABAA 
receptor agonist, to the rat paw also suppressed nocifen-
sive responses, while a dose five times higher resulted in 
increased nocifensive responses to formalin [14]. Together, 
these results in animals suggest that activation of periph-
eral GABAA receptors may result in a local analgesic or 
hyperalgesic effects in a concentration related manner.
Intramuscular injection of glutamate (0.5 M, 0.2 mL) 
into the masticatory muscles of healthy human subjects 
produces pain of moderate intensity (4–6/10) that lasts for 
10–15 min [13, 16–23]. This pain is reported as being more 
intense by women than by men [11, 22]. Injection of glu-
tamate at a higher concentration (1.0 M, 0.2 mL) can also 
produce a longer-lasting (~90 min) mechanical sensitiza-
tion of the masseter muscle which is similar in both sexes 
[22]. In humans, glutamate-induced pain and mechani-
cal sensitization can be attenuated by local injection of 
ketamine, which indicates that they are mediated, in part, 
through activation of peripheral N-methyl-D-aspartate 
(NMDA) receptors [17, 19, 20, 24]. Masseter muscle biop-
sies from healthy subjects have identified NMDA receptor 
expression in a subgroup of sensory nerve fibers [25]. As 
a result of these properties of intramuscular glutamate 
injection, it has been used to model acute masseter muscle 
pain and sensitivity reported by patients suffering from a 
myofascial temporomandibular disorder [19].
The purpose of the present study was to see if find-
ings in rats of a GABAA mediated antinociceptive effect 
could be translated into healthy human subjects. Human 
subjects were given injections of GABA at concentrations 
that had been shown to reduce nociceptive input from the 
rat temporomandibular joint [12, 13]. However, since injec-
tion of these substances into the healthy human temporo-
mandibular joint was not feasible for ethical reasons, the 
study was instead conducted using intramuscular injec-
tions into the masseter muscle. It was hypothesized that 
injections of GABA alone into the muscle would produce 
no more pain than injection of saline, and that injection of 
GABA with glutamate would attenuate glutamate-evoked 
muscle pain in a concentration-related manner that was 
enhanced by the GABAA receptor positive allosteric modu-
lator, lorazepam.
2   Methods
The experimental protocol was approved by the North 
Denmark Ethics Committee (reference no. N-20160037) 
and carried out according to the Helsinki Declaration 
and the IASP guidelines. Written informed consent was 
obtained from all participants.
Thirty healthy volunteers (15 men and 15 women) were 
recruited for study one, and 30 additional healthy volun-
teers (15 men, 15 women) for study two. Two subjects, both 
women, withdrew from study two. Baseline demographics 
for subjects in both studies are provided (Table 1). Both 
studies were randomized, placebo-controlled, double-
blinded, and had a crossover design. Subjects were eli-
gible to participate in the study if they were between 20 
and 40 years of age and free from ongoing or chronic pain. 
Subjects who were pregnant, or intended to become preg-
nant, were breast feeding, had signs or symptoms of any 
serious systemic diseases including malignancies or high 
Table 1: Baseline parameters.
Study   Subjects   Number  Age (years)   PPT (kPa)   PPTOL (kPa)   MJO (mm)
1   Men   15  26 ± 1   161 ± 23   411 ± 45   53 ± 2
1   Women   15  28 ± 1   188 ± 13   377 ± 22   49 ± 2
2   Men   15  25 ± 1   203 ± 16   478 ± 50   52 ± 2
2   Women   13  27 ± 1   153 ± 9   350 ± 48   51 ± 2
The table indicates the mean (± SE) baseline pressure pain threshold (PPT), pressure pain tolerance (PPTOL) and maximum jaw opening 
(MJO) averaged over all sessions for subjects in study 1 (GABA alone) and study 2 (GABA and glutamate). The only significant difference in 
baseline values was for PPT in study 2, where the men had a significantly higher PPT value than women. Bold text: Students t-test, p < 0.05.
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blood pressure, required chronic administration of psychi-
atric, analgesic or other medications that might influence 
their response to pain, reported any recreational drug or 
alcohol use, reported a previous neurologic, musculoskel-
etal or mental illnesses or lacked the ability to cooperate, 
were excluded from participation in the study.
2.1   Study one
This project was designed to test whether intramuscular 
injection of GABA alone is painful and/or alters responses 
to mechanically-induced muscle pain. Each subject 
attended two sessions with a minimum interval of 1 week 
between sessions (Fig. 1A). Treatments were assigned ran-
domly, and neither the subject nor the tester was aware of 
the content of the injections.
Two injections were given in each session with an 
interval of at least 1 h between injections. Injections were 
made into the right, then subsequently into the left mas-
seter muscle in each session. Subjects were instructed 
to continuously rate their pain after the injections. Bilat-
eral masseter muscle pressure pain threshold (PPT) and 
pressure pain tolerance (PPTOL) as well as maximal 
 jaw-opening (MJO) were assessed at baseline and 
periodically after injections (Fig. 1A). After each injection, 
subjects were also asked to draw their perceived distribu-
tion of pain on a picture of the profile of the face.
2.2   Study two
This study investigated whether GABA can modulate 
pain evoked by injection of glutamate into the masseter 
muscle. Subjects attended four sessions in total, each 
lasting 1 h and with an interval at least 1 week between 
sessions (Fig. 1B). During each session, two injections into 
the right masseter muscle were made at a 30 min interval. 
The first injection was glutamate 0.5 M alone, and served 
as an internal control. The second injection was of gluta-
mate 0.5 M randomly combined with various concentra-
tions of GABA (0, 0.05, or 0.5 M) alone or with lorazepam 
(GABA 0.5 M, lorazepam 1  mg/mL) to determine how 
GABA modulates pain and mechanical sensitivity induced 
by injection of glutamate.
Subjects were instructed to continuously rate their 
pain after each injection. PPT and MJO were measured 
5 min before, and then again 5, 10 and 15 min after each 
injection. PPTOL was assessed 5  min before, and then 







Glutamate 0.5 M & GABA 0.0, 0.05, 0.5
M or Glutamate 0.5 M, GABA 0.5 M &
Lorazepam 1 mg/mL
Injection 1 (Internal control)








Intramuscular injection (0.2 mL):
i) GABA 0, 0.05 or 0.5 M, or GABA
0.5 M & lorazepam 1 mg/mL
0 5 10 15 20 25 30 35 40 45–5





Fig. 1: (A) The drawing shows the structure of study I. (B) The drawing shows the structure of study II.
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of PPT. After each injection, subjects were also asked to 
draw their perceived distribution of pain on a picture of 
the profile of the face.
2.3   Measurement of pain and mechanical 
sensitivity
Subjects were instructed to continuously rate their 
pain after injections on an electronic 10-cm computer-
ized visual analogue scale (VAS; sampling rate 0.2  Hz). 
The lower endpoint of the VAS scale is labeled “no pain 
at all” and the upper endpoint labeled “the worst pain 
imaginable”.
Masseter muscle PPT (mean of three trials per side 
per time point) and PPTOL were measured with a Somedic 
Algometer (1  cm2 probe). During these assessments, the 
subjects were asked to keep their jaw at rest and not to 
clench their teeth. The algometer probe was pressed 
against the testing site with a constant advancing rate 
of 50 (Study 1) or 30 (Study 2) kPa/s and subjects push a 
button to stop the stimulation as soon as they felt pain 
(PPT) or could no longer tolerate pain (PPTOL). MJO was 
measured with a ruler in millimeters (mm). At the end of 
each experiment, subjects were asked to their perceived 
region of pain on a paper containing an image of the face 
in profile.
2.4   Injections
Injections (0.2  mL) were made into the deep masseter 
muscle midway between its upper and lower border and 
approximately 1 cm posterior to its anterior border over 
a 5–10 s period with a 27-gauge hypodermic needle and 
disposable syringe. Sterile stock solutions of pH neutral 
GABA (1 M) and glutamate (1 or 2 M) for injection were 
manufactured for the study by a hospital pharmacy 
(Skanderborg Apotek, Denmark). Lorazepam (4 mg/mL, 
Temesta) and buffered sterile saline were purchased from 
the same hospital pharmacy. Solutions for injection were 
made up prior to injection according to the randomiza-
tion table by a member of the research team (SL) who 
did not further participate in the data collection. Sterile 
solutions of GABA (0.05 or 0.5 M), GABA 0.5 M and loraz-
epam (1 mg/mL) were made by diluting stock solutions 
in phosphate buffered saline (PBS). Sterile solutions of 
glutamate 0.5 M with GABA (0, 0.05, or 0.5 M) alone or 
with lorazepam (GABA 0.5 M, lorazepam 1 mg/mL) were 
made by diluting stock solutions in phosphate buffered 
saline (PBS).
2.5   Statistics
The sample size for each study was calculated with a 
risk of type I and type II errors of 5% and 20%, respec-
tively, and a conservative estimate of the intra-individual 
variation of 30% on the VAS with the minimal relevant 
difference to detect as 25%. A total of 24  subjects were 
estimated to be required for each study paradigm (12 men, 
12 women). However, it was anticipated that as many as 
20% of subjects might drop out, and thus 30 subjects for 
each study were recruited.
Data from the recorded electronic VAS was used to 
determine the following pain parameters: peak pain, pain 
duration and area under the VAS curve. Pain area was cal-
culated by summing the VAS scores after each injection. The 
VAS data was assessed using a 2-way  repeated-measures 
ANOVA, with sex and treatment as factors run on the 
program Sigma Plot (Sigma Plot 12, Systat Inc., CA, USA). 
In study one, raw VAS parameters were assessed. In study 
two, the response to the second injection was normalized 
to the response to the first injection to control for interses-
sion variability in raw pain ratings, and the normalized 
data assessed for statistical significance.
Data from measurements of PPT, PPTOL and MJO was 
recorded on an Excel spreadsheet. PPT and MJO data was 
assessed using a 2-way repeated-measures ANOVA, with 
time and treatment as factors run on the program Sigma 
Plot. PPTOL data was assessed with a 1-way-repeated 
measures ANOVA, with treatment as the factor. Drawings 
of pain area were scanned, and the digital images imported 
into the image-processing program ImageJ (National 
Institutes of Health, USA). Area (in arbitrary units) was 
obtained using this software program. Pain area was 
assessed using a 2-way repeated-measures ANOVA, with 
sex and treatment as factors with Sigma Plot.
The Holm-Sidak method was used for post-hoc assess-
ments as appropriate. For all statistical tests employed, a 
p-value of less than 0.05 was considered significant.
3   Results
3.1   Study 1
Injection of GABA was more painful than injection of 
isotonic saline, but overall, pain evoked by GABA was 
mild (<3/10). Injection of GABA 0.5  M was rated more 
painful than injection of either isotonic saline or GABA 
0.05 M (Fig. 2A). This was reflected in significantly higher 
peak and AUC values for GABA 0.5  M with or without 
Brought to you by | Aalborg University Library
Authenticated
Download Date | 1/30/20 12:38 PM
Meijs et al.: The pro-algesic effect of γ-aminobutyric acid (GABA) injection      143
lorazepam (Fig. 2B). The addition of lorazepam with 
GABA 0.5  M further increased pain ratings compared 
with GABA 0.5 M. Peak pain ratings for the combination 
of GABA and lorazepam were significantly higher than 
GABA 0.5  M alone (Fig. 2B). There were no statistically 
significant differences between male and female subjects 
in these parameters.
There were no significant effects of any of the injected 
substances on PPT, PPTOL or MJO over the time course 
of the experiment (Fig. 3). There were no significant sex-
related differences in the baseline values of these three 
parameters (Table 1).
Significant treatment effects similar to those found for 
average pain were found for pain area (Fig. 4). Injections 
Time (s)













GABA 0.05 M 
GABA 0.5 M 




GABA 0.05 M 
GABA 0.5 M





















GABA 0.05 M 
GABA 0.5 M

















GABA 0.05 M 
GABA 0.5 M



















Fig. 2: (A) The line graphs illustrate the mean masseter muscle pain intensity produced by injection of GABA with or without lorazepam, 
compared to saline in the 30 subjects. (B) The bar graphs indicate the mean area under the pain curve (AUC), peak and duration of pain 
produced by injection of the substances indicated. There was a significant concentration-related increase in GABA-evoked overall (F = 6.223, 
p < 0.001) and peak (F = 19.237, p < 0.001) muscle pain, and a non-significant increase in the duration of pain. The addition of lorazepam 
to GABA 0.5 M injections resulted in a significantly higher peak pain rating than GABA 0.5 M alone, which suggests that pain was being 
mediated through activation of GABAA receptors. Asterisks: p < 0.05 compared to saline control; Error bars: SE.
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of GABA 0.5  M with and without lorazepam resulted in 
subject drawings of significantly greater pain area than 
injection of isotonic saline or GABA 0.05 M. Female sub-
jects drew significantly larger areas of pain after injection 
of GABA 0.5 M than did male subjects.
3.2   Study 2
Injection of glutamate 0.5 M alone as an internal control 
produced moderate pain, with average ratings of just 
Time (min)
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Fig. 3: (A) The line and scatter plot shows the mean relative 
pressure pain threshold (PPT) normalized to baseline (−5 min). 
There was no significant effect of any of the injections on PPT.  
(B) The bar graphs indicate the mean relative pressure pain 
tolerance (PPTOL) 5 and 45 min after masseter muscle injections. 
There was no significant effect of any of the injections on the PPTOL. 
(C) The line and scatter plot shows the mean maximal jaw opening 
(MJO). There was a significant decrease in MJO over time (F = 3.426, 
p = 0.011), but no significant effect of treatment or treatment time 


























Fig. 4: (A) The image shows composite pain area drawings from the 
30 subjects. Pain was generally localized to the site of injection with 
all treatments. (B) The bar graphs show the mean pain area. There was 
a significant effect of treatment (F = 11.489, p < 0.001). The drawn pain 
areas for GABA 0.5 M with or without lorazepam were significantly 
larger than those drawn for saline. There was no significant difference 
between areas drawn for GABA 0.05 M and saline or between GABA 
0.5 M with lorazepam and without lorazepam. Asterisks: p < 0.05 
compared to saline control; Error bars: SE.
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under 4. Overall and peak pain produced by the initial 
glutamate injection was reported as significantly greater 
by women than by men (Table 2).
Repeated injection of glutamate evoked pain of 
similar intensity and duration (Fig. 5A). The addition of 
GABA 0.5 M to the glutamate in the second injection sig-
nificantly increased overall, peak and duration of pain 
reported (Fig.  5B). However, the addition of lorazepam 
to the glutamate/GABA 0.5  M injection did not further 
increase pain.
Analysis of the pain parameters also revealed a sig-
nificant interaction between sex and treatment. In men, 
the addition of GABA 0.5 M with glutamate in the second 
injection evoked significantly greater overall and peak 
pain than glutamate alone (Fig. 6). However, in women, 
the addition of GABA 0.5  M with or without lorazepam 
in the second injections did not significantly alter pain 
ratings compared to glutamate alone. When men and 
women were compared, men reported a significantly 
greater enhancement of their pain by GABA 0.5 M added 
to glutamate than women (Fig. 6B).
There were no significant treatment effects on PPT, 
PPTOL or MJO over the time course of the experiment 
(Fig. 7). The only significant sex-related difference found 
was in the baseline PPT value, which was significantly 
higher in men than in women. No other sex-related differ-
ences in these parameters were identified.
There were no significant treatment effects on pain 
area. There was also no sex-related difference in average 
pain area for the initial glutamate injection when areas 
from men and women were compared.
4   Discussion
Preclinical studies have reported that activation of periph-
eral GABAA receptors can exert either analgesic or algesic 
effects, depending on the concentration used [12–14]. 
The present study found that injection of GABA alone 
into the masseter muscle of healthy humans resulted 
in  concentration-related reports of mild pain that was 
further increased by lorazepam, a GABAA receptor posi-
tive allosteric modulator. These results suggest that 
intramuscular injection of GABA excites muscle nocicep-
tors through activation of GABAA receptors. Subsequent 
experiments examined the effect of GABA administration 
on pain evoked by intramuscular injection of glutamate, 
which provokes pain responses through activation of 
peripheral NMDA receptors [17]. These experiments indi-
cated that GABA can, in a concentration-related manner, 
increase glutamate-evoked masseter muscle pain. This 
pro-algesic effect of GABA was significantly greater in men 
than in women. The effect of GABA injections in either sex 
are apparently short lasting, as they did not significantly 
affect mechanical nociception within 5  min of an intra-
muscular injection. Taken together, these results suggest 
that GABA can act through the peripheral GABAA receptor 
in humans to provoke and enhance masseter muscle pain.
The peripheral effect of elevated GABA concentra-
tions on nociception has previously been investigated in 
the skin, joint and oral cavity of rats. Injection of GABA 
into the temporomandibular joint of male rats resulted 
in a concentration related declination in the magnitude 
of the glutamate-evoked TMJ-jaw muscle reflex in male 
rats [12, 13]. This effect could be reversed by bicuculline, 
a GABAA receptor antagonist, but not phaclofen, a GABAB 
receptor antagonist, which indicates it was mediated 
through activation of GABAA receptors. However, subcu-
taneous injection of the GABAA receptor agonist muscimol 
was shown to differentially modulate responses in the 
formalin model of cutaneous inflammatory pain which 
depended on concentration [14]. At low concentration, 
muscimol exerted analgesic effects, whereas at increased 
concentration it enhanced formalin-evoked nocifensive 
behavior. More recently, oral administration of musci-
mol to the tongue was shown to significantly increase the 
mechanical thresholds of tongue afferent fibers compared 
to vehicle, but only after the tongue had been heated 
with 60 °C water [26]. It was also shown in this study 
that 95% of afferent fibers innervating the rat tongue 
mucosa express GABAA receptors [26]. GABA containing 
oral rinses have been recently employed in humans to 
test their effect on burning pain induced by topical appli-
cation of capsaicin [27]. In these experiments, capsaicin 
was applied to the tongue to provoke burning pain, and 





Duration (s) 571 ± 120 395 ± 75
The mean (± SE) area under the pain curve (AUC), peak and duration 
of muscle pain evoked by the first injection of glutamate in men and 
women over four sessions are shown. Women reported significantly 
greater overall pain (AUC) and higher intensity of pain (peak) than 
did men. Bold text: Students t-test, p < 0.05.
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did not alter the peak pain, but did shorten the time for 
healthy human subjects to stop feeling the burning pain 
[27]. Taken together, these previous results demonstrate 
that peripheral GABAA receptor activation can exert very 
different effects that are dependent on the tissue to which 
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Fig. 5: (A) The line graphs illustrate the mean masseter muscle pain intensity produced by injection of glutamate (time 0) followed 30 min 
later by glutamate with GABA (0.05 or 0.5 M) or GABA 0.5 M with lorazepam in 28 healthy subjects. Repeat injection of glutamate alone 
(control) evoked relatively reproducible pain responses. The addition of GABA 0.5 M, with or without lorazepam, in the second injection 
increased the pain intensity compared to injection of glutamate alone. (B) The bar graphs indicate the mean relative area under the pain 
curve (AUC), relative peak and relative duration of pain produced by injection of the substances indicated. There was a significant effect 
of treatment on overall pain (AUC) (F = 4.094, p = 0.009), peak pain (F = 3.021, p = 0.035), and duration of pain (F = 3.444, p = 0.021). The 
addition of GABA 0.5 M significantly increased pain compared to control injections. The addition of lorazepam lowered pain ratings 
compared to GABA 0.5 M without lorazepam. GABA 0.05 M had no effect on glutamate-evoked muscle pain. Asterisks: p < 0.05 compared to 
saline control; Error bars: SE.
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In the spinal cord and trigeminal sensory nucleus, 
GABA acts via the GABAA receptor to mediate primary affer-
ent depolarization; a presynaptic inhibitory mechanism 
[5–9]. This is thought to occur because the chloride rever-
sal potential in central endings of primary afferent fibers 
is more depolarized than the resting membrane potential. 
Indeed, in vivo experiments in the rat have shown that 
sustained application of GABA to the dorsal root ganglion 
neurons results in biphasic depolarization as long as 
GABA is present [28–30]. However, the environment that 
central terminals and sensory ganglion neurons are in may 
be quite different from that of their peripheral endings in 
various tissues, and thus it can only be speculated that the 
resting membrane potential in these endings is similar to 
that measured in sensory ganglion neurons. The finding 
that intramuscular injection of GABA was painful, and 
that GABA could enhance glutamate-evoked muscle pain 
is suggestive that GABA can depolarize peripheral affer-
ent endings, at least in masticatory muscle, and that this 
mechanism contributes to its algesic effects. Why then, 
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Fig. 6: (A) The line graphs illustrate the mean masseter muscle pain intensity produced by injection of glutamate (time 0) followed 
30 min later by glutamate with GABA 0.5 M in men (n = 15) and women (n = 13). Note that the initial injection of glutamate alone produced 
substantially less pain in men than in women (see Table 2). Further, the graphs illustrate that in men, there was a substantial increase in 
pain ratings when glutamate and GABA were injected together, whereas in women, the pain responses appear almost identical. (B) The bar 
graphs indicate the mean relative area under the pain curve (AUC), relative peak and relative duration of pain produced by injection of the 
substances indicated in men (black) and women (white). There was a significant interaction between sex and treatment for AUC (F = 5.005, 
p = 0.003). In men, the combination of GABA 0.5 M with glutamate significantly increased AUC, peak pain, and duration of pain compared  
to glutamate alone. In women, none of these injections had significantly altered pain ratings compared with glutamate alone.  
Asterisks: p < 0.05 men compared with women; Error bars: SE.
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in other tissues at different concentrations, does GABA 
administration result in analgesia? The analgesic effect of 
GABAA receptor activation in preclinical studies has been 
speculated to be due to a current shunt or depolarization 
block [12, 14, 26]. It has been shown that GABA produces 
greater depolarizations of Aβ and Aδ afferent fibers, than of 
C fibers [6]. There is a good temporal relationship between 
the firing of a population of Aδ afferent fibers in rats and 
the change in pain in human subjects, after injection of 
glutamate into the masseter muscle [31]. This may mean 
that much of the acute pain response evoked by glutamate 
when injected into the human masseter muscle is coded by 
the firing of Aδ afferent fibers and thus that GABA, through 
its stronger depolarizing action on myelinated fibers acts 
to increase pain intensity reports. A recent report also indi-
cated that GABA has the ability to activate neuromuscular 
nicotinic receptors at high concentration, which could lead 
to low level muscle contraction [32]. In the present study, 
subjects commonly reported that the muscle felt tight after 
GABA and glutamate were co-injected. If GABA induces 
low levels of muscle contraction, this may also contribute 
to increased pain reports [33]. Indeed, this difference might 
also help explain why GABA increased glutamate-evoked 
pain when injected into the human masseter muscle, but 
decreased glutamate-evoked nocifensive response when 
injected into the rat temporomandibular joint.
The effects of GABA can also be mediated through 
activation of G-protein linked GABAB receptors, which 
are expressed by around one third of trigeminal ganglion 
neurons that innervate the rat masseter muscle (Cairns, 
unpublished results). Baclofen, a GABAB receptor selec-
tive agonist has been shown to exert suppressive effects 
on the responses of vagal and pelvic afferent fibers to 
mechanical stimulation in ferrets and rats, respectively 
[34, 35]. Baclofen has also been shown to increase a tran-
sient and a sustained potassium current in trigeminal 
ganglion neurons, which results in membrane hyperpo-
larization and decreased excitability [36]. However, GABA 
injection into the human masseter muscle did not alter 
PPT or PPTOL, either alone or in combination with glu-
tamate. This suggests that if sensory afferent fibers that 
innervate the human masseter muscle express GABAB 
receptors, their activation by injection of GABA does not 
result in a detectable change in mechanical sensitivity.
Both healthy men and women were recruited into the 
present study to test whether there are sex-related dif-
ferences in the effect of intramuscularly injected GABA. 
While no sex-related differences were found for pain AUC, 
duration or intensity after injection of GABA alone into 
the masseter muscle, it was found that GABA significantly 
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Fig. 7: (A) The line and scatter plot shows the mean relative 
pressure pain threshold (PPT) normalized to the pre-injection 
baseline. There was no significant effect of any of the second 
injections on PPT. (B) The bar graphs indicate the mean relative 
pressure pain tolerance (PPTOL) 45 min after the second masseter 
muscle injections. There was no significant effect of any of the 
injections on the PPTOL. (C) The line and scatter plot shows the 
mean maximum jaw opening (MJO). There was no significant effect 
of any of the second injections on MJO. Error bars: SE.
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enhanced glutamate-evoked masseter muscle pain in men 
but not in women. It is a consistent finding that injection 
of glutamate 0.5 M into the masseter muscle evokes signif-
icantly more pain in women than in men (Table 2) [19, 22, 
37]. However, the combination of GABA 0.5 M with gluta-
mate evoked muscle pain of relatively similar intensity in 
men and women (Fig. 5). If one simply adds the intensity 
of pain produced by GABA alone (Fig. 1B) to the pain pro-
duced by glutamate alone (Table 1) for men, it is a pretty 
good estimate of the pain reported when GABA 0.5  M 
and glutamate were injected together in men. A similar 
estimation for women, suggests that peak pain intensity 
produced by the combination GABA 0.5 M and glutamate 
should have been around 6. It is not clear why pain pro-
duced by injection of glutamate and GABA together were 
not also additive in women. It is possible this sex-related 
difference in the enhancement of glutamate-evoked pain 
by GABA is merely a methodological artifact.
In conclusion, the present study was unable to trans-
late findings of analgesic actions of activation of periph-
eral GABAA receptors from animal models into healthy 
human subjects. Indeed, the findings support the cur-
rently accepted concept that activation of GABAA receptors 
on sensory primary afferent fibers leads to depolarization 
and increased excitability. However, it is important to rec-
ognize that the actions of peripherally administered GABA, 
with regard to algesic versus analgesic effect, appear to 
differ depending on the tissue tested (oral mucosa versus 
skeletal muscle). The mechanistic basis for these differ-
ences in the effect of GABA remain to be determined.
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